Relationships between dose to the gastro-intestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancer

Authors

  • Maria Thor Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, USA
  • Caroline E. Olsson Division of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, the Sahlgrenska Academy at the University of Gothenburg, Sweden
  • Jung Hun Oh Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, USA
  • Stine E. Petersen Departments of Medical Physics and Oncology, Aarhus University Hospital, Aarhus, Denmark
  • David Alsadius Oncology, University of Gothenburg, Gothenburg, Sweden
  • Lise Bentzen Departments of Medical Physics and Oncology, Aarhus University Hospital, Aarhus, Denmark
  • Niclas Pettersson Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden
  • Ludvig P. Muren Departments of Medical Physics and Oncology, Aarhus University Hospital, Aarhus, Denmark
  • Ann-Charlotte Waldenström Division of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, the Sahlgrenska Academy at the University of Gothenburg, Sweden
  • Morten Høyer Departments of Medical Physics and Oncology, Aarhus University Hospital, Aarhus, Denmark
  • Gunnar Steineck Division of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, the Sahlgrenska Academy at the University of Gothenburg, Sweden
  • Joseph O. Deasy Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, USA

DOI:

https://doi.org/10.3109/0284186X.2015.1063779

Abstract

Background. Gastrointestinal (GI) morbidity after radiotherapy (RT) for prostate cancer is typically addressed by studying specific single symptoms. The aim of this study was to explore the interplay between domains of patient- reported outcomes (PROs) on GI morbidity, and to what extent these are explained by RT dose to the GI tract.

Material and methods. The study included men from two Scandinavian studies (N = 211/277) who had undergone primary external beam radiotherapy (EBRT) for localized prostate cancer to 70–78 Gy (2 Gy/fraction). Factor analysis was applied to previously identified PRO-based symptom domains from two study-specific questionnaires. Number of questions: 43; median time to follow-up: 3.6–6.4 years) and dose-response outcome variables were defined from these domains. Dose/volume parameters of the anal sphincter (AS) or the rectum were tested as predictors for each outcome variable using logistic regression with 10-fold cross-validation. Performance was assessed using area under the receiver operating characteristic curve (Az) and model frequency.

Results. Outcome variables from Defecation urgency (number of symptoms: 2–3), Fecal leakage (4–6), Mucous (4), and Pain (3–6) were defined. In both cohorts, intermediate rectal doses predicted Defecation urgency (mean Az: 0.53–0.54; Frequency: 70–75%), and near minimum and low AS doses predicted Fecal leakage (mean Az: 0.63–0.67; Frequency: 83–99%). In one cohort, high AS doses predicted Mucous (mean Az: 0.54; Frequency: 96%), whereas in the other, low AS doses and intermediate rectal doses predicted Pain (mean Az: 0.69; Frequency: 28–82%).

Conclusion. We have demonstrated that Defecation urgency, Fecal leakage, Mucous, and Pain following primary EBRT for localized prostate cancer primarily are predicted by intermediate rectal doses, low AS doses, high AS doses, or a combination of low AS and intermediate rectal doses, respectively. This suggests that there is a domain-specific dose-response for the GI tract. To reduce risk of GI morbidity, dose distributions of both the AS region and the rectum should, therefore, be considered when prescribing prostate cancer RT.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2015-10-21

How to Cite

Thor, M., Olsson, C. E., Hun Oh, J., Petersen, S. E., Alsadius, D., Bentzen, L., … Deasy, J. O. (2015). Relationships between dose to the gastro-intestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancer. Acta Oncologica, 54(9), 1326–1334. https://doi.org/10.3109/0284186X.2015.1063779

Issue

Vol. 54 No. 9 (2015): Acta Oncologica

Section

Articles